Ilofotase alfa 在心脏术后肾损伤高风险患者中的多中心随机双盲安慰剂对照2期试验
这项2期多中心随机双盲安慰剂对照试验纳入术前eGFR 25–65 ml/min/1.73m²、拟行复杂体外循环心脏手术的成人患者,围术期静脉给予两剂ilofotase alfa(128 mg)或安慰剂。共244例随机,204例接受两剂并纳入分析(ilofotase alfa 109例,安慰剂95例)。主要终点术后5天内最高血肌酐/术前比值两组无差异(1.21±0.42 vs 1.27±0.50,p=0.31);MAKE60发生率15.9% vs 15.4%(p=0.87)。未发现安全性问题。
要点
- 适用人群:术前eGFR 25–65 ml/min/1.73m²、拟行复杂体外循环心脏手术的成人患者。
- 干预:围术期静脉给予两剂ilofotase alfa 128 mg或安慰剂;最终204例接受两剂并纳入分析。
- 主要终点:术后5天内最高血肌酐/术前比值,ilofotase alfa组1.21±0.42 vs 安慰剂组1.27±0.50,p=0.31,无差异。
- 次要终点:60天MAKE发生率15.9% vs 15.4%,p=0.87,无差异。
- 安全性:未发现ilofotase alfa相关安全性问题。
适用人群与场景
- 成人患者,术前eGFR 25–65 ml/min/1.73m²,拟行复杂体外循环心脏手术,存在术后肾功能损伤高风险。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 围术期静脉给予两剂ilofotase alfa 128 mg或安慰剂(原文未提及具体给药间隔、频次细节及目标值)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:2期多中心随机双盲安慰剂对照试验,两臂平行设计;共244例随机,204例接受两剂并纳入分析(ilofotase alfa 109例,安慰剂95例)。
- 主要终点:术后5天内最高血肌酐/术前比值,ilofotase alfa组1.21±0.42 vs 安慰剂组1.27±0.50,p=0.31。
- 次要终点:60天MAKE发生率15.9% vs 15.4%,p=0.87。
- 安全性:未发现ilofotase alfa相关安全性问题。
证据类型、等级与局限
- 证据类型:多中心随机双盲安慰剂对照2期试验;原文未提及证据等级或推荐强度。
- 局限:原文未明确列出局限性;样本量204例纳入分析,为2期探索性试验。
对床旁实践的改变
- 本试验结果不支持在体外循环心脏术后肾损伤高风险患者中常规使用ilofotase alfa来预防肾功能损伤,因主要和次要肾脏终点均未改善。
- 适用人群为术前eGFR 25–65 ml/min/1.73m²、拟行复杂体外循环心脏手术的成人;不适用于该人群之外的患者。
- 常见陷阱:不应将本试验中围术期两剂128 mg的方案外推为其他剂量、其他心脏手术类型或非体外循环手术的推荐。
指南或共识出处
- 原文未提及指南或共识出处;试验注册号:EUCT Number 2023-505859-45,US IND Number 117 605,ClinicalTrials.gov ID NCT06168799。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Acute impairment of kidney function after cardiac surgery is common and associated with an increased morbidity and mortality. Ilofotase alfa has demonstrated potential to attenuate renal injury through its immunomodulatory effects. We evaluated the safety and efficacy of ilofotase alfa in preventing renal functional impairment in cardiac surgery patients.
METHODS: This phase 2, multi-center, randomized, double-blinded, placebo-controlled trial employing a two-arm, parallel-group design randomized adult patients at a high risk of renal functional impairment after on-pump cardiac surgery. Patients with a pre-existent estimated glomerular filtration rate of 25-65 ml/min/1.73m2 scheduled to undergo complex cardiac surgery were eligible. Patients received two intravenous doses (128 mg) of ilofotase alfa or placebo perioperatively. The primary endpoint was the ratio between the highest serum creatinine levels within five days postoperative relative to the pre-operative level (sCrRatio). The secondary endpoint was major adverse kidney events up to day 60 (MAKE60).
RESULTS: In total, 244 patients were randomized of whom 204 received two doses and were included in the trial analysis: 109 patients were treated with ilofotase alfa and 95 received placebo. The mean±SD sCrRatio in the ilofotase alfa group was 1.21±0.42, compared to 1.27±0.50 for placebo (p=0.31). MAKE60 incidence was 15.9% in the ilofotase alfa group and 15.4% in the placebo group (p=0.87). No safety concerns were raised.
CONCLUSION: Administration of ilofotase alfa did not attenuate short- and longer-term renal function loss in patients at a high risk of renal functional impairment after on-pump cardiac surgery. No safety concerns of ilofotase alfa emerged.
TRIAL REGISTRATION: EUCT Number: 2023-505859-45 US IND Number: 117 605 ClinicalTrials.gov ID: NCT06168799.
参考来源
- Mourisse L, Ostermann M, Thiessen S, et al. A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery. Intensive Care Med. 2026. PMID: 42766022. doi:10.1007/s00134-026-08596-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。